Naamidine J
Based on 1 Customer Validation
Naamidine J is an imidazole-type alkaloids discovered in a sponge. Naamidine J inhibits inflammation by binding to the protein CSE1L (KD = 5.41 μM). Namidine J significantly inhibits the expression of pro-inflammatory factors such as TNF-α, IL-1β, and IL-6, and upregulates anti-inflammatory factors such as CD206 and Arg-1. Namidine J inhibits PD-L1 and shows antitumor activity. Namidine J significantly reduces pulmonary tissue edema, inflammatory cell infiltration and cytokine storm in mice. Namidine J can be used for the research on the immune microenvironment of acute lung injury and tumors.
For research use only. We do not sell to patients.
- Purity : 99.41%
- CAS No.: 2227550-73-2
- Formula: C25H27N5O5
- Molecular Weight:477.51
-
Storage:
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
Biological Activity
Description
IC50 & Target
[2]|
IL-1β |
IL-6 |
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| HeLa | IC50 |
4.43 μM
Compound: Naamidine J
|
Cytotoxicity against human HeLa cells assessed as reduction in cell viability measured after 72 hrs by SRB assay
Cytotoxicity against human HeLa cells assessed as reduction in cell viability measured after 72 hrs by SRB assay
|
[PMID: 37040446] |
| HepG2 | IC50 |
0.31 μM
Compound: Naamidine J
|
Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay
Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay
|
[PMID: 37040446] |
| K562 | IC50 |
0.62 μM
Compound: Naamidine J
|
Cytotoxicity against human K562 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay
Cytotoxicity against human K562 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay
|
[PMID: 37040446] |
| K562 | IC50 |
11.3 μM
Compound: Naamidine J
|
Cytotoxicity against human K562 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
Cytotoxicity against human K562 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
|
[PMID: 37040446] |
| RKO | IC50 |
>40 μM
Compound: Naamidine J
|
Cytotoxicity against human RKO cells assessed as reduction in cell viability after 24 hrs by CCK8 assay
Cytotoxicity against human RKO cells assessed as reduction in cell viability after 24 hrs by CCK8 assay
|
[PMID: 37040446] |
In Vitro
Naamidine J (5 μM, 24 h) has cytotoxicity against K562 cells with an IC50 of 11.3 μM but is not toxic to macrophages and RKO cells (IC50 > 40 μM)[1][2].
Naamidine J (10 μM, 24 h) reduces PD-L1 expression in RKO cells and PDAC cells[1][3].
Naamidine J (1-5 μM, 5 h) inhibits the Inflammatory response in LPS (HY-D1056)-induced RAW264.7 macrophages[2].
Naamidine J (5 μM, 5 h) inhibits nuclear translocation of transcription factor SP1 mediated by CSE1L in LPS-induced macrophages[2].
Naamidine J (10 μM, 24 h) restores the cytotoxicity of CD8+ T cells and significantly reduce the survival of PDAC cells (MIA-PaCa2, BxPC-3)[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:RKO cells
-
Concentration:10 μM
-
Incubation Time:24 h
-
Result:Had a certain inhibitory effect on PD-L1 expression.
-
Cell Line:RAW264.7 cells
-
Concentration:1, 2 and 5 μM
-
Incubation Time:Pre-treatment for 3 hours, followed by co-stimulation with LPS for 2 hours
-
Result:Exhibited concentration-dependent inhibition of TNF-α release.
-
Cell Line:RAW264.7 cells
-
Concentration:1, 2 and 5 μM
-
Incubation Time:Pre-treatment for 3 hours, followed by co-stimulation with LPS for 2 hours
-
Result:Inhibited pro-inflammatory factors (TNF-α, IL-1β, IL-6), and promoted anti-inflammatory factors (CD206, Arg-1).
-
Cell Line:RAW264.7 cells
-
Concentration:5 μM
-
Incubation Time:Pre-treatment for 3 hours, followed by co-stimulation with LPS for 2 hours
-
Result:Resulted in the accumulation of SP1 in the cytoplasm.
Enhanced the interaction between CSE1L and SP1.
In Vivo
Naamidine J (30 mg/kg, i.p., once every three days for 28 days) significantly enhances the proportion of CD8+ Tex subset and reduced the proportion of intermediate CD8+ Tex subset in mice bearing subcutaneous tumors with high NAT10 expression[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Acute lung injury model established in mice[2]
-
Dosage:10 and 20 mg/kg
-
Administration:Intraperitoneal injection (i.p.), once daily for 3 days
-
Result:Significantly reduced the increase in lung organ coefficient induced by LPS and alleviate pulmonary edema.
Significantly improved the pathological damage of lung tissue and reduce the infiltration of inflammatory cells.
Significantly reduced the protein levels of TNF-α in serum and lung tissue, as well as the mRNA expression of various inflammatory factors.
Reduced the proportion of pro-inflammatory M1-type macrophages in the lung tissue and increased the proportion of anti-inflammatory M2-type macrophages.
-
Animal Model:PanO2 xenograft model established in four-week-old female C57BL/6 mice (18 to 20 g)[3]
-
Dosage:30 mg/kg
-
Administration:Intraperitoneal injection (i.p.), once every three days for 28 days
-
Result:Significantly inhibited tumor growth in the Nat10-OE group.
Reversed T cell exhaustion and restores anti-tumor function.
Increased the infiltration of CD8+ T cells, reduced the PD-1 with IFNγ and exhausted phenotype, and increased the PD-1-IFNγ+ cytotoxic phenotype.
Chemical Information
-
CAS No. 2227550-73-2
-
Appearance Solid
-
Molecular Weight 477.51
-
Formula C25H27N5O5
-
Color Off-white to light yellow
-
SMILES
O=C1N=C(C(N1C)=O)NC2=NC(CC3=CC=C(C=C3)OC)=C(CC4=CC=C(C(OC)=C4)OC)N2C
-
Structure Classification
-
Initial Source
Pericharax heteroraphis
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
Solvent & Solubility
In Vitro:
DMSO : 4.55 mg/mL (9.53 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Protocols
-
RNA extraction experimental
By lysing cells, releasing RNA, and removing impurities such as proteins and DNA, high-purity RNA products are finally obtained. The commonly used traditional method is the guanidine isothiocyanate/phenol/chloroform method (Trizol), which is suitable for a variety of animal materials including animal tissues, microorganisms, cultured cells, etc., and most plant materials.
-
Research Protocol for Inflammation-related Diseases
The NLRP3 inflammasome is a cytosolic innate immune signaling platform that integrates priming signals and danger-signal activation to promote caspase-1 activation, maturation of IL-1β and IL-18, and gasdermin D-mediated pyroptotic cell death. The core experimental logic is to determine whether inflammatory disease phenotypes are driven by increased NLRP3 expression, ASC-containing inflammasome assembly, caspase-1 cleavage, GSDMD cleavage, and extracellular release of IL-1β/IL-18 rather than by nonspecific cell injury alone. The pathway is strongly linked to inflammation-related disease phenotypes because monosodium urate crystals activate NALP3/NLRP3 inflammasome signaling in gout-like crystal inflammation, cholesterol crystals activate NLRP3 inflammasomes in atherogenesis models, and DSS-induced intestinal inflammation has been reported to involve NLRP3 inflammasome activity. However, experimental colitis studies also show context-dependent protective effects of NLRP3 inflammasome co
-
Subcutaneous Cell-Line-Derived Xenograft
Subcutaneous cell-line-derived xenograft (CDX) models are established by implanting cultured human cancer cell lines into immunodeficient mice, where the injected cells form localized tumors that can be monitored in vivo as a measure of tumorigenic potential, growth kinetics, and treatment response. These models are widely used in oncology research because they allow reproducible tumor formation and enable comparative assessment of tumor growth between different cell lines or genetic manipulations in a controlled in vivo microenvironment. Subcutaneous implantation of cancer cells in immunodeficient mice is a standard approach for evaluating tumor growth behavior and therapeutic response across multiple cancer types, including prostate, esophageal, pancreatic, and colon cancer models.
-
Inhalation Toxicity Study
Inhalation toxicity studies expose rodents to a controlled aerosol, vapor, gas, or smoke atmosphere and assess respiratory and systemic toxicity using exposure-atmosphere characterization, clinical observations, body and organ weights, bronchoalveolar lavage fluid, histopathology, blood chemistry, hematology, and, when included, molecular endpoints such as transcriptomics, proteomics, lipidomics, or tissue burden analysis. The primary biological readouts are airway irritation, pulmonary inflammation, cytotoxicity, altered surfactant or lipid homeostasis, impaired particle clearance, and tissue remodeling, reflected by BALF cell differentials, BALF protein, LDH, phosphatase activities, cytokines, lung weight, microscopic respiratory-tract lesions, and retained lung burden.
-
Pyroptosis Solutions
Pyroptosis is a lytic inflammatory cell-death pathway executed by gasdermin pores, most classically through inflammasome-mediated activation of caspase-1, cleavage of gasdermin D, membrane pore formation, LDH release, and secretion of IL-1β and IL-18. The canonical pathway is commonly modeled by priming cells with an inflammatory signal such as LPS to induce pro-IL-1β and inflammasome components, followed by an activation signal such as ATP or nigericin to activate NLRP3, ASC speck formation, caspase-1 cleavage, GSDMD cleavage, cytokine release, and pyroptotic membrane rupture. The non-canonical pathway is triggered when cytosolic LPS activates mouse caspase-11 or human caspase-4/5, leading to GSDMD cleavage and pyroptosis, and this can secondarily activate NLRP3-dependent IL-1β release. Pyroptosis is linked to inflammatory injury, infection, cancer, liver disease, ocular disease, placental inflammation, and other disease phenotypes, but unresolved questions include which gasdermin fam
Purity & Documentation
-
Data Sheet (285 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Handling Instructions (2659 KB)
References
[1]. Fu PP, et al. Bioactivity-Driven Synthesis of the Marine Natural Product Naamidine J and Its Derivatives as Potential Tumor Immunological Agents by Inhibiting Programmed Death-Ligand 1. J Med Chem. 2023 Apr 27;66(8):5427-5438. [Content Brief]
[2]. Gao CL, et al. Chemoproteomics of Marine Natural Product Naamidine J Unveils CSE1L as a Therapeutic Target in Acute Lung Injury. J Am Chem Soc. 2024 Oct 16;146(41):28384-28397. [Content Brief]
[3]. Chen E, et al. NAT10 regulates tumor progression and immune microenvironment in pancreatic ductal adenocarcinoma via the N4-acetylated LAMB3-mediated FAK/ERK pathway. Cancer Commun (Lond). 2025 Sep;45(9):1162-1187. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.0942 mL | 10.4710 mL | 20.9420 mL | 52.3549 mL |
| 5 mM | 0.4188 mL | 2.0942 mL | 4.1884 mL | 10.4710 mL |